Collectively, the progression from exenatide to tirzepatide illustrates how extending the half-life of GLP-1R agents and incorporating additional mechanisms of action has led to substantial improvements in both glycemic control and weight loss
10.2989/17280583.2019.1674660 Summary Keywords functional gastrointestinal disorders, migraine, vomiting, antiemetics, anticonvulsants, cyclic vomiting syndrome, differential diagnosis, episodic syndromes that may be associated with migraine Citation Raucci U, Borrelli O, Di Nardo G, Tambucci R, Pavone P, Salvatore S, Baldassarre ME, Cordelli DM, Falsaperla R, Felici E, Ferilli MAN, Grosso S, Mallardo S, Martinelli D, Quitadamo P, Pensabene L, Romano C, Savasta S, Spalice A, Strisciuglio C, Suppiej A, Valeriani M, Zenzeri L, Verrotti A, Staiano A, Villa MP, Ruggieri M, Striano P and Parisi P (2020) Cyclic Vomiting Syndrome in Children
Subcutaneous Absorption Kinetics of Tirzepatide in Type 2 Diabetes Patients
However, if obese patients are not successful, intense behavioral treatment or pharmacotherapy is used
